We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.025 | -1.18% | 2.10 | 2.10 | 2.16 | 2.20 | 2.10 | 2.20 | 112,953 | 13:05:41 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
Date | Subject | Author | Discuss |
---|---|---|---|
06/4/2018 08:01 | Immupharma £15 billion takeover target. | englishlongbow | |
06/4/2018 08:01 | Are we nearly there yet? | ewads | |
06/4/2018 08:00 | 10k bought on bell | opodio | |
06/4/2018 07:58 | Dr Bio. Thanks. We now know your agenda. Your posts carry zero value. | roundup | |
06/4/2018 07:58 | The share is so moreish. makes me want to just buy more but thats because it becomes a constant money machine soon, a golden goose, 96% margins on ANNUAL £100bn sales including other indications | opodio | |
06/4/2018 07:57 | Looks like a gaggle of golden geese to me. What about the other platforms? | runtoma | |
06/4/2018 07:55 | must pain these guys like Dr Bio and hamham watching from the outside looking in and watching price go into orbit if i see big buy trades in today i will triple large positions. Ready to mobilise troops as we go over 180p and look forward to 600p next week | opodio | |
06/4/2018 07:55 | Level 2 early indicators 170/175 | ny boy | |
06/4/2018 07:54 | it becomes a constant money machine, a golden goose, 96% margins on ANNUAL £100bn sales including other indications yesterdays 250k buyer may have had early peek at P3 results...smiling | opodio | |
06/4/2018 07:53 | How expensive do you think an RNS is?They haven't issued an RNS because the data isn't locked yet. The working day has hardly started: I would expect an announcement later today or possibly even Monday morning. | longshanks | |
06/4/2018 07:53 | you smell like a gone off ham | opodio | |
06/4/2018 07:50 | it becomes a constant money machine, a golden goose, 96% margins on ANNUAL £100bn sales including other indications yesterdays 250k buyer may have had early peek at P3 results...smiling | opodio | |
06/4/2018 07:49 | Chart shows we have broken through the upside of the trend channel and heading to test 190p resistance. | ny boy | |
06/4/2018 07:46 | it becomes a constant money machine, a golden goose, 96% margins on ANNUAL £100bn sales including other indications | opodio | |
06/4/2018 07:44 | Look out for the £15 billion takeover announcement. | englishlongbow | |
06/4/2018 07:37 | They may shortly be.... | glennrcharles | |
06/4/2018 07:36 | They’re not going to post a very expensive RNS to tell us what we already know. They’re not made of money | pretax2 | |
06/4/2018 07:36 | Imo, RNS for the locking of data will be issued today. We know professor Muller will be talking about Lupuzor at the conference on Monday. In fact I would not be surprised if following the locking of data today, they announce the P3 results on Monday prior to the conference call. It makes sense to do it that way. This is how I interpret it and it is my personal view. | hjs | |
06/4/2018 07:30 | My prediction is that Lupuzor will replace Benlysta as "many drugs have failed lupus trials because they try to suppress the immune system" - and this is where Lupuzor comes at the top and and this is the breakthrough. Regarding anyone questioning, out of the blue "this or that", please be reminded that the IMM Scientific Team is from the prestigious CNRS and have donkeys of years of experience and they know exactly what they are doing. So when Lupuzor replaces Benlysta, I am sure there will be many who will retire earlier than expected. | fuji99 | |
06/4/2018 07:25 | 28 March 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") Appointment of Joint Broker ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker to act alongside Northland Capital Partners who remain the Company's Nominated Adviser and joint corporate broker. Tim McCarthy, Chairman of ImmuPharma, commented: "We welcome Bryan Garnier as Joint Broker. Bryan Garnier provides ImmuPharma with deep healthcare expertise and pan European broking capability, to support the Company as we progress towards commercialisation." Olivier Garnier, Founder and Managing Partner of Bryan, Garnier & Co. commented: "We are delighted to be appointed and we look forward to working with the Company at this very exciting time." | opodio | |
06/4/2018 07:25 | opodio - coockoo! | hamhamham1 | |
06/4/2018 07:24 | buy at 600p next week babies | opodio | |
06/4/2018 07:20 | Are we there yet? | ewads | |
06/4/2018 07:20 | Dr biotech great post | best1467 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions